Vertex Pharmaceuticals Stock Three Year Return
VRTX Stock | USD 397.27 0.63 0.16% |
Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
Vertex |
Vertex Pharmaceuticals Company Three Year Return Analysis
Vertex Pharmaceuticals' Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
More About Three Year Return | All Equity Analysis
Three Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.
Competition |
Based on the latest financial disclosure, Vertex Pharmaceuticals has a Three Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Vertex Three Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Three Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.Vertex Pharmaceuticals is currently under evaluation in three year return category among its peers.
Vertex Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Vertex Fundamentals
Return On Equity | -0.0298 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | (0.05) % | ||||
Operating Margin | 0.41 % | ||||
Current Valuation | 97.49 B | ||||
Shares Outstanding | 257.53 M | ||||
Shares Owned By Insiders | 0.07 % | ||||
Shares Owned By Institutions | 96.14 % | ||||
Number Of Shares Shorted | 3.67 M | ||||
Price To Earning | 24.57 X | ||||
Price To Book | 6.55 X | ||||
Price To Sales | 9.63 X | ||||
Revenue | 9.87 B | ||||
Gross Profit | 5.32 B | ||||
EBITDA | 4.61 B | ||||
Net Income | 3.62 B | ||||
Cash And Equivalents | 9.77 B | ||||
Cash Per Share | 38.06 X | ||||
Total Debt | 808.4 M | ||||
Debt To Equity | 0.06 % | ||||
Current Ratio | 4.70 X | ||||
Book Value Per Share | 60.65 X | ||||
Cash Flow From Operations | 3.54 B | ||||
Short Ratio | 2.64 X | ||||
Earnings Per Share | (1.91) X | ||||
Price To Earnings To Growth | 1.04 X | ||||
Target Price | 498.24 | ||||
Number Of Employees | 5.4 K | ||||
Beta | 0.39 | ||||
Market Capitalization | 102.31 B | ||||
Total Asset | 22.73 B | ||||
Retained Earnings | 10.14 B | ||||
Working Capital | 10.6 B | ||||
Current Asset | 1.41 B | ||||
Current Liabilities | 506.35 M | ||||
Net Asset | 22.73 B |
About Vertex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.